CoChat

Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss

Open access
Durell, Natalie, Franks, Rachel, Coon, Scott, Cowart, Kevin, Carris, Nicholas W. · 2022 · Journal of Pharmacy Technology

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Background: Depression and obesity have a bidirectional relationship making the management of one, without the other, problematic. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a preferred medication class for diabetes and obesity treatment given their weight loss effect; however, it is not known how antidepressants impact this effect. Objective: To assess the impact of antidepressant use on GLP-1 RA-associated weight loss in patients with or without type 2 diabetes mellitus. Methods: This was a retrospective, propensity matched, cohort study conducted using TriNetX. The study identified patients initiating a GLP-1 RA being treated with citalopram/escitalopram, bupropion, or no antidepressant. Cohorts were propensity score matched to analyze the primary outcome of mean end-of-study (77-371 days) body weight. Results: An initial query identified 31 273 patients eligible for analysis (30 160 receiving no antidepressant, 311 receiving bupropion, and 802 receiving citalopram/escitalopram). After propensity score matching, the study found patients receiving citalopram/escitalopram were taking more antidiabetic therapies at baseline compared with patients not treated with an antidepressant. Patients in the antidepressant cohorts experienced less weight loss compared with their respective matched cohorts not receiving antidepressants (citalopram/escitalopram −0.73 kg versus −1.74 kg; bupropion −0.84 kg versus −3.46 kg). Only the bupropion cohort was significantly heavier at end-of-study versus the non-antidepressant cohort (108 kg versus 103 kg, P = 0.018). Conclusion and Relevance: Antidepressants may diminish the weight loss effect of GLP-1 RAs. Additional research is needed to assess whether all GLP-1 RAs are affected similarly and the optimal weight loss strategies in patients receiving antidiabetic therapy with comorbid depression.

Overview

Integrity signals

Registry

Crossref · 10.1177/87551225221110850

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 21 references

Cited by

See all 16

Metadata

Authors
Durell, N., Franks, R., Coon, S., Cowart, K., & Carris, N. W.
Affiliations
  • University of South Florida (US)
  • BayCare Health System (US)
  • Orlando VA Medical Center (US)
Corresponding author
Carris, Nicholas W.
Venue
Journal of Pharmacy Technology
Published
2022-07-29
Volume
38
Issue
5
Pages
283-288
ISSN
  • 1549-4810 (ISSN-L)
  • 8755-1225
OpenAlex
W4288696768
Cited by
15
References
21
Citations by year
2026: 1 · 2025: 9 · 2024: 3 · 2023: 1 · 2022: 1
FWCI
2.09
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Journal of Pharmacy Technology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
antidepressants, GLP-1 receptor agonists, weight loss, depression, obesity, type 2 diabetes, citalopram, escitalopram, bupropion, drug-drug interactions, antidiabetic therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss. https://app.cochat.ai/papers/10.1177/87551225221110850
The paper
Durell, N., Franks, R., Coon, S., Cowart, K., & Carris, N. W. (2022). Effect of Antidepressants on Glucagon-Like Peptide-1 Receptor Agonist-Related Weight Loss. Journal of Pharmacy Technology. https://doi.org/10.1177/87551225221110850

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.